Harvard Bioscience director granted 16,556 RSUs
Benson Seth Benjamin reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Benson Seth Benjamin reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Seth Benjamin Benson received a grant of 16,556 restricted stock units of common stock, awarded at a price of $0.0000 per share. This equity award will vest in full immediately before the company’s next annual meeting or one year from the grant date, whichever comes first.
After this grant, Benson directly holds 27,556 shares of common stock, including the new award and 11,000 shares already beneficially owned. The filing also notes a 10-for-1 reverse stock split of Harvard Bioscience common stock that occurred on March 13, 2026, which adjusted previously reported award amounts.
Insider Trade Summary
Grant/Award: 16,556 shares
Grant/Award
1 txn
Insider
Benson Seth Benjamin
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 16,556 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 27,556 shares (Direct)
Footnotes (3)
- F1. Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
- F2. Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person.
- F3. On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Key Figures
RSU award size: 16,556 restricted stock units
Grant price per share: $0.0000 per share
Total shares after transaction: 27,556 shares
+3 more
6 metrics
RSU award size
16,556 restricted stock units
Equity grant to director on June 9, 2026
Grant price per share
$0.0000 per share
Restricted stock unit award to director
Total shares after transaction
27,556 shares
Director’s direct holdings following the grant
Previously beneficially owned shares
11,000 shares
Shares beneficially owned by the reporting person
Reverse stock split ratio
10-for-1
Common stock reverse split on March 13, 2026
Reverse split date
March 13, 2026
Effective date of 10-for-1 reverse split
Key Terms
restricted stock units, reverse stock split, beneficially owned, common stock
4 terms
restricted stock units financial
"Represents an award of 16,556 restricted stock units that vests in full"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
reverse stock split financial
"the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
beneficially owned financial
"11,000 shares of common stock beneficially owned by the Reporting Person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
common stock financial
"The 11,000 shares referenced in Footnote 2(b) were previously reported"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Harvard Bioscience (HBIO) report for Seth Benjamin Benson?
Harvard Bioscience reported that director Seth Benjamin Benson received 16,556 restricted stock units of common stock as an equity award. The grant, priced at $0.0000 per share, is a compensation-related acquisition rather than an open-market stock purchase or sale.
When do the 16,556 restricted stock units granted to the HBIO director vest?
The 16,556 restricted stock units vest in full either immediately before Harvard Bioscience’s next annual meeting or one year from the grant date, whichever occurs earlier. This creates a single vesting event tied to the company’s governance calendar and the original grant timing.
What reverse stock split did Harvard Bioscience (HBIO) disclose in this Form 4?
The Form 4 notes that on March 13, 2026, Harvard Bioscience common stock underwent a 10-for-1 reverse stock split. A previously reported 110,000 restricted stock units now correspond to 11,000 shares beneficially owned, with all figures adjusted to reflect the split.
Is the Harvard Bioscience (HBIO) director’s transaction an open-market trade?
No, the transaction is classified as a grant or award acquisition, not an open-market trade. The director received 16,556 restricted stock units at $0.0000 per share as part of compensation, rather than buying or selling shares on the open market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
